Multicentre Randomized Study on the Effect Telmisartan Compared to Carvedilol on Lv Mass

Galzerano, Domenico; Viscovo, Luca Del; Tammaro, Paolo; Cerciello, Antonio; Breglio, R; Mallardo, Mario; Tuccillo, Bernardino; Capogrosso, Paolo

doi:10.1097/00004872-200406002-00391

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It competitively inhibits the AT1 receptors to block the RASS system. Studies have shown that telmisartan provides cardiovascular protection similar to that of ACEI drugs while lowering the blood pressure, especially in the prevention and reversal of ventricular remodeling caused by hypertension [12]. At present, research on its cardiovascular protection mainly focuses on its role in the RASS system [13].…”

Section: Discussionmentioning

confidence: 99%

Effects of telmisartan on serum adiponectin and left ventricular remodeling in patients with essential hypertension

Lin¹,

Shi²,

Wei³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

The aim of this study was to observe the changes in the serum Adiponectin (APN) levels and Left Ventricular Hypertrophy (LVH) in hypertensive patients before and after telmisartan treatment. Two hundred and forty hypertensive patients complicated with LVH were divided into a telmisartan group and an amlodipine group. The changes of these patients' blood pressure, APN, and Left Ventricular Mass index (LVMI) treatment before and 12 w after treatment were compared. The systolic and diastolic blood pressures in both groups were significantly lower than those before treatment (P<0.01). The difference in diastolic blood pressures between the two groups was not statistically significant (P>0.05). Serum APN levels in the telmisartan group were significantly higher than those before treatment (P<0.01), while LVMI was significantly lower than before (P<0.01). Serum APN levels and LVMI had no significant changes in the amlodipine group before and after treatment (P>0.05). Compared with amlodipine, telmisartan significantly increased the serum APN levels and significantly reversed the Left Ventricular Remodeling (LVRM) while reducing the blood pressure.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of telmisartan on serum adiponectin and left ventricular remodeling in patients with essential hypertension

Lin¹,

Shi²,

Wei³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

show abstract

“…37 The technique has been used to compare the effect of telmisartan with that of carvedilol, showing that telmisartan produced superior regression of LVH, despite both agents bringing about similar BP reductions. 38 The ONTARGET Cardiac MRI Substudy aims to provide a better understanding of the effects of targeting the RAS, using an ARB and/or ACE inhibitor, on the myocardium. In addition, evaluation of the neurohormone BNP may provide an insight into its prognostic value by examining the correlation between plasma BNP levels with LV structural and functional changes in a large patient population.…”

Section: Discussionmentioning

confidence: 99%

Rationale and Design of the Cardiac Magnetic Resonance Imaging Substudy of the ONTARGET Trial Programme

Anderson

2005

J Int Med Res

View full text Add to dashboard Cite

Angiotensin-converting enzyme (ACE)inhibitors have been shown to improve cardiovascular disease outcomes in highrisk patients, but evidence for the cardioprotective effects of angiotensin II receptor blockers (ARBs) is less extensive. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and the parallel Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) -which together form The ONTARGET Trial Programmeare long-term, large-scale, double-blind, multinational outcome studies with the primary objectives of determining if the combination of the ARB telmisartan 80 mg and the ACE inhibitor ramipril 10 mg is more effective than ramipril 10 mg alone, and if telmisartan is at least as effective as ramipril (in the case of ONTARGET), and if telmisartan is superior to placebo (in the case of TRANSCEND), in providing cardiovascular protection for high-risk patients. A pre-defined substudy is being conducted within The ONTARGET Trial Programme to compare the effects of these agents, alone and in combination, on cardiac structure and function. The substudy overcomes criticisms of many previous studies, which have been performed in small numbers of patients using suboptimal methodology, by evaluating changes in left ventricular structure and function using sophisticated technology provided by magnetic resonance imaging (MRI). Some 300 randomized patients within ONTARGET, recruited from selected centres in Australia, Canada, Germany, Hong Kong, New Zealand and Thailand, will have MRI undertaken at baseline and at 2-year follow-up. As this method of assessing left ventricular dysfunction is somewhat timeconsuming, expensive and complex, and in the light of current interest in the role of B-type natriuretic peptide (BNP) as a simple, inexpensive diagnostic and prognostic tool, the substudy will also examine whether changes in BNP during follow-up correlated with changes in left ventricular dysfunction.

show abstract

“…In the 82 evaluated patients with hypertension and LVH, it was demonstrated that telmisartan was superior to carvedilol in reducing LVM, despite both drugs producing similar reductions in blood pressure. 33 …”

Section: P Verdecchia Telmisartan In Cardiac Remodellingmentioning

confidence: 99%

Pre-Clinical and Clinical Experience of Telmisartan in Cardiac Remodelling

Verdecchia

2005

J Int Med Res

View full text Add to dashboard Cite

Epidemiological studies have established that left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular and cerebrovascular morbidity and mortality. In turn, hypertension is a well-established risk factor for LVH. Ambulatory blood pressure monitoring has shown that 24-h mean ambulatory blood pressure is a particularly powerful predictor of LVH, being superior to casual clinic blood pressure measurements

show abstract

Multicentre Randomized Study on the Effect Telmisartan Compared to Carvedilol on Lv Mass

Cited by 4 publications

References 0 publications

Effects of telmisartan on serum adiponectin and left ventricular remodeling in patients with essential hypertension

Effects of telmisartan on serum adiponectin and left ventricular remodeling in patients with essential hypertension

Rationale and Design of the Cardiac Magnetic Resonance Imaging Substudy of the ONTARGET Trial Programme

Pre-Clinical and Clinical Experience of Telmisartan in Cardiac Remodelling

Contact Info

Product

Resources

About